PATENT CLAIM ANALYSIS

Application Number: 15751954
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "253000"]

Abstract:
The present disclosure relates to a pharmaceutical combination, e.g. a product, comprising a combination of (a) a MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof and a PKC pathway inhibitor of formula III, formula IV, formula V or formula VI or a pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of proliferative diseases. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, data carriers and related disclosure embodiments. The disclosure further relates to use of an MDM2 inhibitor of formula I or formula II, or a pharmaceutically acceptable salt thereof, alone for use in the treatment of a proliferative disease.

Claim (Index 34):
The compound according to  claim 33 , wherein the MDM2i is (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 88.0
- Lexical Diversity: 2.32143
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14647939', '15561209', '15752896', '15341275', '10046681']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.80460275073314
- 35 USC 102 Novelty (BERT): 0.5497939181249735
- Combined Prediction Score: 0.7791218674723234
- Mean Citation Score: 340.23294
- Max Citation Score: 410.63678
- Similarity Product: 336.8222384519982

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test